CALLING ALL FUTURE EXPERTS IN RHEUMATOID ARTHRITIS! AT FRAUNHOFER MAKE THE MOST OF YOUR TALENTS BY JOINING OUR FRAUNHOFER IME TEAM IN FRANKFURT. POSTS ARE IMMEDIATELY AVAILABLE FOR:
POST-DOCTORAL RESEARCHER (M/F)
The Fraunhofer Institute for Molecular Biology and Applied Ecology IME conducts research in the field of applied life sciences from a molecular level to entire ecosystems. Our interdisciplinary organization and laboratories with most recent equipment including GMP facilities and complex facilities for environmental simulations allow a wide spectrum of research and development services in the three divisions Molecular Biotechnology, Applied Ecology and Bioresources as well as Translational Medicine.
A postdoc position in a project aimed at the development of new treatment options for rheumatoid arthritis (RA) in humanized experimental mouse models. It is placed at the IME Fraunhofer Institute TMP in Frankfurt am Main, Medical Campus of the Goethe University, Germany with an initial exchange with the Karolinska Institute, Stockholm, Sweden.
What we expect from you
To qualify, the applicant must hold a PhD in medicine or biological science. Training in immunology and experimental studies using mouse models is a requirement. Computer skill and bioinformatics knowledge are needed. Language in both laboratories in Sweden and Germany is English.
What you can expect from us
Applications are invited for a position as a postdoc in a project led by Prof. Rikard Holmdahl and Prof Harald Burkhardt. The task is to analyse and validate new approaches to induce regulatory T cells for the treatment of rheumatoid arthritis using humanized animal models.
The project aims to develop new vaccines for RA based on posttranslational modified peptides complexed with the human class II molecule DR*0401. DR*0401 is an allelic variant of the major histocompatibility complex type II (MHC2) strongly associated with RA. It is based on studies in murine arthritis models, genetically dependent on the corresponding mouse MHC molecule Aq. We have made new mouse strains, with physiological expression of the DR*0401 molecule together with other humanizing mutations to establish new experimental models for RA. The project now aims to validate the pharmacological effects of candidate vaccines for further drug development and to analyse their mechanism of action, based on earlier studies in the Aq-models. Results are aimed to be published in leading international journals.
The project is developed by both scientists at the Karolinska Institute, Stockholm, Sweden, in close collaboration with scientists at the Fraunhofer Institute in Frankfurt. The initial work, which includes training in the animal models and the mouse based immunology assays will be performed at the Karolinska and continued in the Fraunhofer Institute, Frankfurt. The project is long term and will include career support.
Appointment, remuneration and social security benefits based on the public-sector collective wage agreement (TVöD).
The working time consists of 39 hours per week.
The position is initially limited.
In case of identical qualifications, preference will be given to severely disabled candidates.
The Fraunhofer-Gesellschaft is committed to providing equal career opportunities for men and women.
Fraunhofer is Europe’s largest application-oriented research organization. Our research efforts are geared entirely to people’s needs: health, security, communication, energy and the environment. As a result, the work undertaken by our researchers and developers has a significant impact on people’s lives. We are creative. We shape technology. We design products. We improve methods and techniques. We open up new vistas.
In case of any further questions, please do not hesitate to contact:
Professor Rikard Holmdahl, e-mail: Angel Yao Mattisson: Angel.Yao-Mattisson@ki.se or Professor Harald Burkhardt, e-mail: Harald.Burkhardt@ime.fraunhofer.de
For environmental reasons we kindly ask you to only apply online, by pressing the "Apply"-button….
Don't forget to mention Naturejobs when applying.